Is ruxolitinib/ruxolitinib cream available in China? Come check out the latest news!

Ruxolitinib/ruxolitinib cream (ruxolitinib), as a newer topical immunomodulatory drug, is mainly used to treat atopic dermatitis (AD), vitiligo, etc. It has not yet been officially launched in mainland China. Therefore, if domestic patients need to use ruxolitinib cream, they often need to purchase it through overseas channels. In the international market, ruxolitinib cream is available in original and generic versions. However, since China has not yet approved its domestic marketing, these drugs can only be obtained through overseas drug purchases and other channels.

At present, the original ruxolitinib cream is usually produced by pharmaceutical companies in the United States. The specification is1.5%*60g, and the price of each box is about more than 20,000 yuan. Since this drug is an imported drug, the actual price may be affected by exchange rate fluctuations, and the price fluctuates greatly. In addition, the European version of ruxolitinib cream also has similar pricing, and the price may vary depending on the region, which makes the drug more expensive for domestic patients.

In addition to original products, some generic drugs have also begun to enter the market, especially generic versions from countries such as Bangladesh. The ruxolitinib cream produced in Bangladesh has a specification of 1.5%*30g. Each box is priced at more than 600 yuan, which is more affordable than the original version. Due to the large price difference, some patients choose to purchase generic drugs. However, although generic drugs are less expensive, patients need to be careful when choosing, taking into account factors such as drug quality, source and effectiveness.

In general, since ruxolitinib cream has not yet been officially launched in mainland China, domestic patients need to purchase the drug through overseas channels. Despite its higher price, ruxolitinib cream undoubtedly provides an effective new option for some patients with severe atopic dermatitis, especially those who do not respond well to traditional treatments. With domestic attention to this drug and the advancement of regulatory processes, ruxolitinib cream may officially enter the Chinese market in the future to provide treatment options for more patients.

Reference: https://www.opzelura.com/